Skip to main content
N

NOVOGENE CO., LTD. — Investor Relations & Filings

Ticker · 688315 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 556 across all filing types
Latest filing 2026-04-14 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688315

About NOVOGENE CO., LTD.

Novogene Co., Ltd. is a global provider of genomic services and solutions, specializing in next-generation sequencing (NGS) and bioinformatics analysis. The company offers a comprehensive suite of services, including whole genome sequencing, transcriptomics, epigenomics, and metagenomics, alongside specialized solutions for single-cell analysis and clinical diagnostics. Utilizing advanced high-throughput sequencing platforms and proprietary bioinformatics pipelines, Novogene supports research across diverse fields such as human health, agriculture, and environmental science. The organization serves a broad client base encompassing academic institutions, pharmaceutical companies, and biotechnology firms. With a focus on data quality and technical expertise, Novogene facilitates large-scale genomic studies and precision medicine initiatives through its network of high-capacity laboratories and integrated data management systems.

Recent filings

Filing Released Lang Actions
北京诺禾致源科技股份有限公司关于2025年年度计提资产减值准备的公告
Regulatory Filings Classification · 1% confidence The document is a standalone corporate announcement by the board of Beijing 诺禾致源科技股份有限公司 regarding the 2025 year‐end asset impairment provisions, including amounts, accounting basis, board and audit committee approvals, and audit confirmation. It is not a full Annual (10‐K) or Interim (IR) report, nor an earnings release, dividend notice, M&A, or other specific category. It is therefore a general regulatory filing by the company, falling into the fallback category “Regulatory Filings (RNS).”
2026-04-14 Chinese
北京诺禾致源科技股份有限公司委托理财制度
Governance Information Classification · 1% confidence The document is an internal policy manual titled "委托理财制度" (“Entrusted Wealth Management System”) detailing corporate governance rules, procedures, risk controls, approvals, and disclosure requirements for entrusted financial management. It is an internal governance document articulating company policies and controls rather than a financial report, announcement, or transaction notice. This aligns with the Governance Information category (CGR).
2026-04-14 Chinese
北京诺禾致源科技股份有限公司关于召开2025年度暨2026年第一季度业绩暨现金分红说明会的公告
Investor Presentation Classification · 1% confidence The document is an announcement by Beijing Novogene Technology Co., Ltd. regarding the scheduling of an investor performance and cash dividend explanation meeting for the 2025 full year and 2026 Q1 results. It does not contain the actual financial results or presentations; rather, it provides details on the date, time, format, participants, and access instructions for an interactive investor event. This corresponds to an investor presentation invitation rather than an earnings release or report publication. Therefore, it falls under the “Investor Presentation” category (Code: IP).
2026-04-14 Chinese
北京诺禾致源科技股份有限公司2025年度“提质增效重回报”行动方案评估报告暨2026年“提质增效重回报”行动方案
Investor Presentation Classification · 1% confidence The document is an internal action-plan assessment report and forward‐looking “提质增效重回报” strategy, laid out as a multi-part slide deck (with page headers like NOVOGENE | 38, 32, etc.), focusing on corporate strategy, investor returns, governance improvements, global expansion, and AI initiatives. It is not a financial statement or regulatory notice but a presentation of strategic plans to investors/stakeholders. Therefore, it best matches the “Investor Presentation” category (IP).
2026-04-14 Chinese
北京诺禾致源科技股份有限公司关于预计2026年度日常关联交易的公告
Regulatory Filings Classification · 1% confidence The document is an official announcement of the company’s expected 2026 daily related-party transactions (‘关联交易’), detailing board and independent director review, counterparties, amounts, and supporting information. It does not present full financial results (Annual Report/10-K, Interim Report/IR), nor is it a dividend notice, earnings release, M&A announcement, capital issuance, management change, ESG report, proxy materials, or similar. It is a regulatory disclosure of related-party transactions under listing rules, which falls under the fallback category of general “Regulatory Filings” (RNS).
2026-04-14 Chinese
北京诺禾致源科技股份有限公司2025年度审计报告及财务报表
Regulatory Filings
2026-04-14 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.